Recent Quotes (30 days)

You have no recent quotes
chg | %

Immunotech Laboratories Inc  

(Public, OTCMKTS:IMMB)   Watch this stock  
Find more results for PINK:IMMB
0.00000 (0.00%)
Delayed:   12:47pm GMT-4
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/943.00
Mkt cap 480,120.00
P/E     -
Div/yield     -
EPS -221.70
Shares 60.56M
Beta 19.15
Inst. own     -

Key stats and ratios

Q3 (Sep '06) 2005
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -187.88% -134384.00%
Return on average equity - -
Employees 4 -
CDP Score - -


116 W Stocker St
United States - Map
+1-818-4212090 (Phone)
+1-818-4098988 (Fax)

Website links


Immunotech Laboratories, Inc. (Immunotech) is a drug development company. The Company is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. Immunotech's key compound Immune Therapeutic Vaccine-1 (ITV-1) is a suspension of Inactivated Pepsin Fraction (IPF), which is for the treatment of human immunodeficiency virus/ acquired immune deficiency syndrome (HIV/AIDS) and Hepatitis C, and to modulate the immune system. The Company's other compounds in its pipeline include ITV-2 prenatal, ITV-3 Pediatric and ITV-4 HIV Vaccine. IPF is a platform technology that can be used to facilitate a range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals. IPF is the active drug substance of ITV-1 and is an extract of porcine pepsin.

Officers and directors

Harry H. Zhabilov Vice Chairman of the Board, Chief Science Officer
Age: 45
Roscoe M. Moore Jr. Ph.D. Director
Age: 70